SelectQuote Inc. Highlights Progress Amid Policy Headwinds

SelectQuote Inc ((SLQT)) has held its Q3 earnings call. Read on for the main highlights of the call.

SelectQuote Inc.’s latest earnings call struck a cautiously upbeat tone as management balanced solid operational gains with clear-eyed acknowledgment of policy and reimbursement headwinds. Revenue and EBITDA both climbed, Senior and Healthcare Services delivered visible progress, and the company underscored strong backbook cash flows, even as it flagged IRA impacts, prior PBM pressure and some timing-related volatility in Medicare Advantage approvals.

Consolidated Revenue Growth

SelectQuote reported consolidated revenue of $431 million for the quarter, representing a 6% year-over-year increase despite regulatory and reimbursement noise. Management framed this growth as validation that the company’s diversified platform can expand even in a more challenging post-IRA environment.

Adjusted EBITDA Expansion

Adjusted EBITDA rose 18% year-over-year to $45 million, underscoring improving profitability as the company scales its Senior and Healthcare Services businesses. Excluding a favorable $14 million change in estimate, management said the consolidated EBITDA margin would have been around 7%, highlighting underlying progress but also the importance of normalizing for one-time items.

Senior Segment Strength

The Senior business remained the company’s profit engine, with revenue up 8% to $183 million and approved Medicare Advantage policies growing 4%. Senior adjusted EBITDA reached $59 million, and even excluding the $14 million adjustment, the segment posted a 26% margin and has sustained 25% or higher profitability during the AEP and OEP seasons for four straight years.

Commissions Receivable and Backbook Visibility

SelectQuote emphasized its nearly $1 billion Medicare Advantage commissions receivable balance as a key asset supporting long-term cash flows. The company booked a $14 million favorable change in estimate tied to higher expected renewals and pointed to a recapture rate around 34%, reinforcing confidence in the durability and visibility of backbook economics.

SelectRx Member and Operational Momentum

Healthcare Services, led by SelectRx, generated $199 million in revenue with membership of roughly 117,000, up 11% year-over-year, signaling steady adoption. Over two years, prescriptions shipped climbed 64%, and SelectRx’s adjusted EBITDA improved sequentially to $5 million, indicating that scaling volumes are beginning to translate into earnings traction.

Path to Meaningful SelectRx Profitability

Management reiterated that SelectRx is on track to reach a $40 million to $50 million EBITDA run rate in the very near term, positioning the platform as a significant future profit contributor. This outlook rests on continued operational gains and the ability to leverage the infrastructure already in place across the pharmacy and services footprint.

Facility Efficiency and Scalability

The Olathe, Kansas distribution facility remains a key efficiency lever, currently handling less than 20% of prescriptions while delivering more than 30% productivity gains versus legacy sites. With substantial unused capacity, SelectQuote sees room to shift more volume to Olathe over time, further lowering unit costs and supporting margin expansion.

Marketing and Productivity Improvements

Agent productivity has inched higher, with policies per agent up 1% compared with two years ago, as the company fine-tunes its sales processes. Marketing efficiency also improved, with 14% less spent per approved policy and a consolidated revenue-to-CAC multiple of 6.7x, suggesting stronger returns on customer acquisition despite a competitive landscape.

Life Insurance Steady Contribution

The Life segment provided a stable, if modest, profit stream with revenue rising 4% to $48 million and adjusted EBITDA of $6 million. Final Expense commissions grew more than 8% year-over-year and remained the standout growth driver, helping offset softer term life sales amid changing consumer media habits and pricing competition.

Inflation Reduction Act Impact on Revenue

The Inflation Reduction Act, which imposed maximum fair prices on certain high-cost drugs starting January 1, reduced sequential top-line revenue for SelectRx. While the company received $13 million in manufacturer refunds and described the EBITDA hit as in the low single-digit millions, management acknowledged that these policy changes are reshaping revenue recognition and economics in the pharmacy business.

PBM Reimbursement and Earlier Headwinds

SelectRx faced carrier-specific PBM reimbursement actions earlier in the year that pressured revenue and margins, creating short-term volatility. Management said rates have now normalized and a multi-year agreement has been secured, suggesting that this particular headwind has abated, although it underscored the sensitivity of the model to payer behavior.

One-Time Accounting Adjustment Aiding Results

A $14 million favorable change in estimate to commissions receivable enhanced quarterly profitability, contributing to the 18% adjusted EBITDA growth headline. Executives defended the adjustment as data-driven but acknowledged it is non-recurring, and investors will likely strip it out to gauge the sustainability of earnings improvement.

Potential Timing Risk in Senior Approval Rates

Approval rates for Medicare Advantage policies were materially higher in the latest OEP than in prior years, boosting volumes and revenue in the quarter. Management cautioned that some of this may reflect a pull-forward of business from the upcoming quarter, creating uncertainty around Q4 approved policy levels and the cadence of future revenue recognition.

Term Life Competitiveness

Term life sales faced pressure from intensified competition and evolving consumer media consumption, which weighed on segment upside. While Final Expense remained a bright spot, the company acknowledged that broader life trends and marketing dynamics are constraining growth in term products and requiring ongoing adjustments in strategy.

Market Valuation Disconnect

Executives repeatedly highlighted what they see as a sharp disconnect between the company’s nearly $1 billion in commissions receivable and a market capitalization they said sits below $200 million. This valuation gap, in management’s view, reflects investor skepticism about monetizing backbook cash flows and is prompting consideration of multiple strategic options to unlock value.

Forward-Looking Guidance and Outlook

SelectQuote reaffirmed fiscal 2026 guidance for revenue of $1.61 billion to $1.71 billion and adjusted EBITDA of $90 million to $100 million, signaling confidence despite policy changes and timing noise. Management expects to exit fiscal 2026 on strong footing, deliver meaningful year-over-year improvements in operating cash flow, compound cash-flow growth into 2027 and gradually reduce leverage.

SelectQuote’s call painted the picture of a business leaning on durable Senior economics and a maturing SelectRx platform to drive improved cash generation, even as regulatory shifts and payer behavior inject near-term uncertainty. For investors, the story hinges on whether the company can convert its sizable commissions backbook and operational gains into sustained, less volatile cash flows that ultimately close the perceived valuation gap.